Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEYOND: Phase 3 Trial of BION-1301 in Adults With IgA Nephropathy
jRCT2061240045Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in IgA nephropathy (IgAN) comparing BION-1301 600 mg Q2W with Placebo Q2W (2 arms). Primary endpoint: Change in proteinuria from baseline to Week 40. Started Jul 2024; status: recruiting.
02
Drugs
zigakibart
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on jRCT2061240045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061240045.